Sherwood, OR, United States

Entia Biosciences

entiabio.com
Sherwood, OR, United States
SEARCH FILTERS
Time filter
Source Type

PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical trials” results has been accepted for presentation at the ASN Kidney Week 2016 Annual Meeting November 17-20 in Chicago, at the McCormick Place Convention Center.  The presentation is titled: “ErgoD2 Medical Food Therapy: A Novel Strategy to Delay Progression of Chronic Kidney Disease (CKD).” “The acceptance of our CKD clinical trial study for presentation is evidence of the Society’s interest in the potential of our technology,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  It is indeed an honor for our Company and we are looking forward to showing a large audience of nephrologists from the United States and the world the therapeutic value of adding our ErgoD2® medical food to the CKD patient standard of care that is currently available.” Chronic Kidney Disease takes a significant toll on the health of more than 25 million individuals in the U.S. alone.  Progression of the disease leads to dialysis, and eventually the need for a kidney transplant.  The cost to the U.S. Healthcare system was reported as $42.5 billion in 2009 by the National Institutes of Health, and has been growing at a compound rate of +9.8% annually. The product being tested is a specific proprietary blend of Entia’s patented ErgoD2 technology.  Entia Biosciences is the first company to develop, produce and market consumer products with all-natural formulas for the amino acid L-ergothioneine and enhanced vitamin D2.   This novel medical food is a supplement to a patient’s existing prescribed regimen of care and is intended to increase kidney filtration rates, improve iron levels and increase production of red blood cells.  If the study proves successful, Entia’s ErgoD2 product formulation for Chronic Kidney Disease will provide patients with the first all-natural, organic medical food product designed to improve the health and well-being of the patient, enhance the dietary management of the disease and potentially slow its progression. The application of medical foods containing ErgoD2 formulations is not limited to Chronic Kidney Disease; Entia believes that ErgoD2’s ability to improve iron homeostasis has the potential to mitigate many other chronic disease conditions related to iron dysfunction.  Entia plans to address several disease markets, all characterized by dysfunctional iron disorders, in which it believes its products may be of significant efficacy.  These disorders are also associated with oxidative stress and inflammation and include, but are not necessarily limited to, Anemia, Chronic Kidney Disease, Autism and various neurodegenerative diseases, such as Parkinson's and Multiple Sclerosis. Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and conditioning), and prevention and repair of injuries, including improving or maintaining muscle mitochondrial health, stimulating muscle mitochondrial biogenesis as well as other indications as set forth herein. In addition, pharmaceutical, nutraceutical and nutritional medical food compositions that are useful in conditions, normal or abnormal, associated with mitochondrial dysfunction and altered biogenesis in organ systems consisting of skeletal muscle, smooth muscle and cardiac muscle are also disclosed. L-Ergothioneine (also referred to as Ergothioneine or ET), Vitamin D2 (Ergocalciferol) and/or other antioxidants are disclosed for use in pharmaceutical, nutraceutical and nutritional medical food compositions for uses to stimulate production of bioactive molecules, including but not limited to glutathione, alpha synuclein, and IL-6.


Nutritional products, including food and/or beverage compositions, pharmaceutical and cosmetic preparations and methods of use are disclosed for the prevention, suppression and treatment of skin, hair, and nail conditions for the improvement of skin, hair and nail growth through the identification and/or use of stem cells, as well as maintenance of healthy tissues. Uses of Ergothioneine and/or Vitamin D to neutralize free radicals, and improve skin, hair and nail growth are disclosed.


Nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of Ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2^(+) charge for proper oxygen binding and carrying are further disclosed. The extraction of Ergothioneine from whole food sources and bacterium for use in nutritional products, compositions, pharmaceutical preparations and treatments is also disclosed.


PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of the University of Cologne, Germany.  Through a predecessor entity, Entia exclusively licensed this patent, its European Application (Number 5745195.7-2401) and the technology associated therewith in a license agreement with the University of Cologne in December of 2008. Previous companion patents for the same inventions were granted in the United States, Canada and Israel and were exclusively licensed to Entia under the aforementioned license. “The grant of this European patent further strengthens our exclusive intellectual property position in this technology across a significant geographic market,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  “Through our soon-to-be-introduced medical food products, we look forward bringing this technology to bear on chronic kidney disease, psoriasis, Parkinson’s disease, multiple sclerosis and autism.” Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of the University of Cologne, Germany.  Through a predecessor entity, Entia exclusively licensed this patent, its European Application (Number 5745195.7-2401) and the technology associated therewith in a license agreement with the University of Cologne in December of 2008. Previous companion patents for the same inventions were granted in the United States, Canada and Israel and were exclusively licensed to Entia under the aforementioned license. “The grant of this European patent further strengthens our exclusive intellectual property position in this technology across a significant geographic market,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  “Through our soon-to-be-introduced medical food products, we look forward bringing this technology to bear on chronic kidney disease, psoriasis, Parkinson’s disease, multiple sclerosis and autism.” Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of the University of Cologne, Germany.  Through a predecessor entity, Entia exclusively licensed this patent, its European Application (Number 5745195.7-2401) and the technology associated therewith in a license agreement with the University of Cologne in December of 2008. Previous companion patents for the same inventions were granted in the United States, Canada and Israel and were exclusively licensed to Entia under the aforementioned license. “The grant of this European patent further strengthens our exclusive intellectual property position in this technology across a significant geographic market,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  “Through our soon-to-be-introduced medical food products, we look forward bringing this technology to bear on chronic kidney disease, psoriasis, Parkinson’s disease, multiple sclerosis and autism.” Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of the University of Cologne, Germany.  Through a predecessor entity, Entia exclusively licensed this patent, its European Application (Number 5745195.7-2401) and the technology associated therewith in a license agreement with the University of Cologne in December of 2008. Previous companion patents for the same inventions were granted in the United States, Canada and Israel and were exclusively licensed to Entia under the aforementioned license. “The grant of this European patent further strengthens our exclusive intellectual property position in this technology across a significant geographic market,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  “Through our soon-to-be-introduced medical food products, we look forward bringing this technology to bear on chronic kidney disease, psoriasis, Parkinson’s disease, multiple sclerosis and autism.” Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of the University of Cologne, Germany.  Through a predecessor entity, Entia exclusively licensed this patent, its European Application (Number 5745195.7-2401) and the technology associated therewith in a license agreement with the University of Cologne in December of 2008. Previous companion patents for the same inventions were granted in the United States, Canada and Israel and were exclusively licensed to Entia under the aforementioned license. “The grant of this European patent further strengthens our exclusive intellectual property position in this technology across a significant geographic market,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  “Through our soon-to-be-introduced medical food products, we look forward bringing this technology to bear on chronic kidney disease, psoriasis, Parkinson’s disease, multiple sclerosis and autism.” Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


PORTLAND, Ore., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) announced that it has licensed to GROH BEAUTY CORP of Deerfield Beach, Florida, the exclusive worldwide rights to manufacture and distribute its proprietary GROH® beauty care product line.  The license also has a companion agreement that provides for Entia to manufacture and supply its proprietary ErgoD2® product for use in GROH BEAUTY CORP's manufacture of the various products within the GROH product line.  Together, the license and its companion manufacturing agreement provide Entia with an upfront license fee, on-going royalties based on sales of products containing the ErgoD2 compound and sales revenue from supply of ErgoD2 to GROH BEAUTY CORP.  “We are very pleased to be working with GROH BEAUTY CORP, a new business unit of a proven, successful developer and marketer of beauty and cosmetic products," stated Carl J. Johnson, President and Chief Executive of Entia.  “We are confident that they will generate significant success with the GROH brand and look forward to the additional resources that this license will provide to us.  This is an alternative but superior approach for Entia to the beauty care market and will better contribute to building value for our shareholders than the Company's previous efforts in this area." Entia’s 2014 entry into the beauty care market did not achieve the success for which the then management had hoped.  Entia's new management has determined that beauty care is not an appropriate area of strategic focus for the Company, planning instead upon developing and profitably marketing clinically-proven health care products that are based upon the Company's novel and proprietary ErgoD2 technology in the nutritional supplement and/or medical food categories. The Company is taking aggressive yet carefully planned steps toward that end.  Dr. Marvin Hausman, Chief Science & Technology Officer, indicated that Entia plans to introduce its first healthcare product before mid-2017.  The product will likely be introduced as a kidney health supplement.  Kidney health is a growing concern in the U.S. and around the world.  "The Company's research studies among individuals with compromised kidney function have been quite encouraging, if not downright exciting," noted Hausman.  "We are anxiously looking forward to the market rollout of the first of our new healthcare products." "We are delighted to be working with Entia Biosciences and taking over the GROH brand," said Mr. Patrick Neville of GROH BEAUTY CORP.  "With Entia's proprietary ErgoD2 compound, the products have characteristics that the beauty market will find quite desirable.  We plan on making GROH a big winner." GROH BEAUTY CORP plans on its initial GROH rollout by midyear.  In the interim, GROH products will still be available from Entia through existing channels. Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®.  The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets.  Entia also develops and markets health-related cosmeceuticals.  Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb. GROH BEAUTY CORP is a newly established business unit of an international developer, manufacturer and marketer of fine beauty products.  It is based in Deerfield Beach, Florida. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission.  Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q.  These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov.  The information contained in this press release is accurate as of the date indicated.  Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Loading Entia Biosciences collaborators
Loading Entia Biosciences collaborators